- NexGel Inc NXGL announced results from its proof-of-concept study for its diclofenac hydrogel patches.
- The patches are designed to treat pain indications such as arthritis, joint pain, muscle aches, and more.
- The study compared NexGel's diclofenac hydrogel patches with the leading commercially available topical treatment.
- It assessed the formulations, skin retention, and permeation of the products through the skin. The results revealed that NexGel's diclofenac hydrogel patches delivered an equivalent dose considerably faster and are longer-acting compared to the current standard of care on a head-to-head basis.
- They also showed gentle skin adhesion for eight to 12 hours.
- Diclofenac patches are nonsteroidal anti-inflammatory drug (NSAIDs) products used to treat short-term pain due to minor strains, sprains, and bruises.
- The early proof-of-concept results validate the potential effectiveness of NexGel's technology in drug delivery patches.
- Last week, NexGel said it had developed a new, proprietary hydrogel eye patch to treat amblyopia, a type of poor vision that typically occurs in one eye but can occur in both eyes (also called lazy eye).
- The patch is expected to be available for ophthalmologists and optometrists to offer to their patients in 1H of 2023.
- Price Action: NXGL shares are trading flat at $1.35 on the last check Tuesday.
Loading...
Loading...
NXGLNexGel Inc
$2.61-4.01%
Edge Rankings
Momentum
43.15
Growth
23.22
Quality
N/A
Value
59.33
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.